About this trial
This study will measure the effects of a brief one-time eLearning intervention on researcher Knowledge, Attitudes, and Perceptions (KAP) of including people with disabilities (PWDs) in biomedical \& behavioral research. Researchers will be recruited from across the Einstein/Montefiore network, and other medical centers with a focus on CTSAs.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Aged >=18
Conducts non-disability focused research (in the past 3 years)
Conducts (primarily) research with/on adults
Affirms their understanding that eligibility and data must pass quality assurance checks before compensation is disbursed
Disqualifiers
Participant in Aim1/Aim2 of D2/R3 study
Respondent fails to provide a valid US-based personal institutional email
Trial design
Parallel
Treatments tested in this trial
eLearning module
Other intervention* Baseline pre-survey (15 minutes) * Baseline learning module (30 minutes) * Baseline post-survey (15 minutes) * Follow-up survey (3-4 weeks later) Components of KAP survey: Demographics-research experience/role, disability status, exposure to PWDs, etc. (baseline pre-survey only; e.g. not asked at post follow-up survey) Knowledge-short-answer, clinical scenarios, items focused on historical/legislative context, etc. Attitudes-validated "Attitudes to Disability Scale" (ADS) developed by a World Health Organization (WHO) working group Perceptions-questions developed by Prosci's Awareness, Desire, Knowledge, Ability, Reinforcement (ADKAR) framework.
Control
Other interventionDisability Statistics Training (University of New Hampshire Link). Modules identify disability data sources via US surveys and measurement hurdles in disability research: A) Module 2/Topic 1 (13m:44s): Operationalization of Disability in Surveys- covers the two common operationalization methods, the 6 Question Sequence (6QS) and the Washington Group Short Set (WGSS), and the challenges of collecting disability data B) Module 3/Topic 1 (13m:48s): Disablement Models- conceptually defines models, such as Nagi's Disablement Model, Work Disability, Verbrugge and Jette, and WHO's Definition.
Treatment groups
Trial outcomes
Primary outcomes
Change in Attitudes Towards Disability
Change in Attitudes will be assessed using the 16 item Attitudes to Disability Scale (ADS). Scoring range on a 5-point Likert scale ranging from 1-5, yielding an overall possible scoring range of 16-80. Participants for whom a single item is inapplicable (i.e., N/A) will have data removed for that item. Lower scores indicate less favorable attitudes towards people with disabilities, while higher scores indicate more favorable attitudes. \*Note: Questions 1-6 \& 11-16 are reverse coded.
Secondary outcomes
Change in Knowledge Scores
Change in Knowledge scores from baseline will be assessed using a 10 item multiple choice scale which assesses how disability is conceptualized, historical and legislative context, etc. Scoring range: 0%-100%, whereby the percentage correct indicates comprehension towards factual items and best practices for engaging people with disabilities. Questions 4, 8, and 10 can be scored for partial credit. Percentage correct scores will be summarized by study arm.
Change in Perception Scores
Change in Perception from baseline will be assessed using a 17 item Change in Perception scale. Scores are based on 5 domains (i.e. Awareness, Desire, Knowledge, Ability, Reinforcement). Scoring range for each domain includes: Awareness (1-5), Desire (2-10), Knowledge (4-20), Ability (4-20), Reinforcement (6-30). An overall composite score of 17-85 for all 5 of these domains. Participants for whom a single item is inapplicable (i.e., N/A) will have data removed for that item. Higher scores indicate greater awareness of, willingness and motivation to include, understanding about, ability to include, and reinforcement of inclusive behavior, respectively, regarding inclusion of people with disabilities in research.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Albert Einstein College of Medicine
Lead sponsor
National Center for Advancing Translational Sciences (NCATS)
Collaborator